Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2220 re-treatment in adults with transthyretin amyloid cardiomyopathy
2025-520506-35-00Phase 2Authorised
- Sponsor
- Neurimmune
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of cliramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Neurimmune. Primary endpoints: Change from baseline to Visit 16 in cMRI and Change from baseline to Visit 16 in scintigraphy. Planned start Jun 2025; status: authorised.
02
Drugs
cliramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2025-520506-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520506-35-00.